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Over 1800 Cystic Fibrosis Transmembrane Conductance Regulator gene (CFTR)mutations have been identiﬁed so far, determining different degrees
of CFTR dysfunction and a range of different cystic ﬁbrosis phenotypes. The P5L CFTR mutation is a recently described N-terminus missense variant
which may cause defect of protein folding and processing/trafﬁcking, but the functional classiﬁcation is still unclear. Given the rarity of the mutation, the
associated clinical phenotype is still unknown. The aim of our study was to describe the clinical phenotypes in a group of 7 patients with the P5L mu-
tation including 2 adults, 2 adolescents and 3 children. The P5L variant was associated with ΔF508 in 5 patients and with W1282X in two patients.
All patients had positive or borderline sweat test values. All had pancreatic sufﬁciency, no hepatobiliary disease, no or mild respiratory symp-
toms and normal lung function. The two adult males were fertile. Most of the patients presented recurrent episodes of dehydration and
hypochloronatremia.
We conclude that, although it has been speculated that the N-terminus CFTR missense variants may severely affect the behaviour of the CFTR
chloride channel, patients with the P5L CFTR mutation, in association with a severe class II mutation, may be asymptomatic or may be affected by
mild disease.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; CFTR; P5L1. Introduction
Cystic fibrosis (CF) is caused by mutations of the CF Trans-
membrane Conductance Regulator gene (CFTR). The classic
CF phenotype includes multi-organ involvement with predom-
inant severe respiratory disease, pancreatic insufficiency and
male infertility [1,2].
In recent years it has been acknowledged that there is a wide
clinical spectrum of disease associated with the CFTR muta-
tions. About 10% of the patients present a mild form of CF
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or borderline sweat test [3–5].
Because of the unusual presentation, the diagnosis of these
“non classic” cystic fibrosis can be difficult to make. The dis-
ease severity, to some extent, correlates with organ's sensitivity
to CFTR dysfunction and with the amount of functional protein
which is influenced by the type of mutation. More than 1800
CF mutations have been described since the cloning of the gene
in 1989, even though the association of genotype–phenotype
has been made only for a few common mutations [6].
The P5L mutation consists an N-terminus CFTR missense
variant which has been recently described in Spain [7]. Eight dif-
ferent N-terminus missense natural variants have been detected
which cause a defect of CFTR folding and or/trafficking, thus se-
verely affecting the chloride channel activity. Although a severe
impact of this CFTR variant has been predicted on the CFby Elsevier B.V. All rights reserved.
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with this mutation to support this hypothesis, perhaps due to its
rarity. The aim of this study was therefore to describe clinical fea-
tures in patients bearing the rare P5L CFTR mutation.
2. Methods
2.1. Patients population
We reviewed data from a cohort of 105 patients with a diag-
nosis of cystic fibrosis followed in the Cystic Fibrosis Centre of
the Catania University Hospital (Southern Italy). All patients
were followed in the Centre since the time of the diagnosis.
Sweat test, clinical data and genotypes were available for all
the patients. Seven patients (5 males, age range 15 months–
30 years) who were heterozygous for the P5L mutation were in-
cluded in the study. The study was approved by our local Com-
mittee for Clinical Investigation and informed consent was
obtained by each patient or parent.
2.2. Diagnostic tests and clinical data
Sweat chloride concentrations were obtained according to
guidelines by the Gibson and Cooke method [8]. Three tests
were performed in each patient and the mean value is reported.
Blood immunoreactive trypsinogen (IRT) was measured in pa-
tients who underwent neonatal screening for CF (in Italy new-
born screening is mandatory since 1998) one and three weeks
after birth. Pancreas sufficiency was defined as a faecal elastase
N200 mg/g faeces. A quarterly clinical evaluation was per-
formed in our Centre after the diagnosis. During each visit
lung function (in patients N6 yrs old) was measured according
to the American Thoracic Standard criteria [9]. Values of forced
expiratory volume in 1 s (FEV1) and forced vital capacity
(FVC) were expressed as % predicted of normal values adjust-
ed for age, gender, sex height and weight. Sputum samples for
microbiology were obtained for all adults and adolescents. In
younger children who could not expectorate sputum, oropha-
ryngeal swabs were collected. Chest High Resolution Comput-
ed Tomography scan (HRCT) was performed in all patients.
Demographic data included in the study were derived from
the last routine evaluation in the Centre. The age at the diagno-
sis was derived from the date of the first sweat test performed.
2.3. Genetic analysis
Genotyping of the CFTR was carried out on DNA extracted
from blood leucocytes. In our laboratory basic genetic test was per-
formed by reverse dot blot hybridisation by using INNO-LiPA
CFTR19 and CFTR17+Tn assays (Innogenetics, Zwiljnaarde,
Belgium). The test, performed according to the recommendation
of the supplier, allows the detection of the 36 more common muta-
tions in Europe [10]. In patients suspected of CF and a single allele
mutation shown by basic genotyping, advanced genetic testing is
routinely performed in our laboratory. The P5Lmutation was iden-
tified by denaturing high-performance liquid chromatography
(d-HPLC) and confirmed by gene sequencing analysis with anautomated procedure (Genetic Analyzer, Applied Biosystems).
Methods and procedures for dHPLC and DNA sequencing
were reported previously [11–13].
3. Results
3.1. Genotype
Advanced genetic analysis showed that 7, out of 105 pa-
tients followed in our Centre, were heterozygous for the P5L
CFTR mutation. Five patients also carried the ΔF508 mutation
in the second allele while two carried the W1282X mutation.
The group included two adults, two adolescents and three chil-
dren. Demographic data of the patients are shown in Table 1.
3.2. Diagnosis
Only three children, who were born after 1998, were
screened for CF. These children had abnormal IRT values and
for this reason the CF diagnosis was made soon after birth
(Table 1). For patient n. 6 hypertrophic pyloric stenosis was
reported after birth. In the other patients the diagnosis was
made during childhood: recurrent episodes of dehydration (in
some cases severe) were the main reason for addressing the
child to the Centre for sweat test evaluation. Four patients had
clearly abnormal sweat chloride values (N60 mmol/l), while
three patients were in the intermediate range (30–60 mmol/l).
3.3. Clinical data and clinical course
All patients were in good nutritional status with two patients
slightly overweight (Table 1). All had pancreatic sufficiency
and no hepatobiliary disease was recorded (Table 2).
Both adults and children had no chronic respiratory symptoms.
Respiratory exacerbations, requiring oral antibiotics prescription
were uncommon in all patients over the time. Patient n. 3 required
i.v. antibiotic once. Chest HRCT showed the absence of bronchi-
ectasis in all patients except in n. 1 (the older of the group), in
which mild bilateral basal bronchiectasis were present.
In all cooperating patients we found a normal lung function
with all FEV1 values well above 80% of predicted. Sputum or
throat swab cultures revealed episodic presence of Staphylococcus
aureus in some patients, while the occurrence of Pseudomonas
aeruginosa in the sputum was reported in one occasion in patient
n. 1 and in three occasions (through the course of life) in n. 3
(Table 2). All patients except n. 4 and n. 7, had recurrent episodes
of dehydration and hypochloronatremia, particularly during the
summer, sometimes so severe to require hospitalisation.
For the two adult males spermiograms were performed and
both revealed normal values. Patient n. 2 also had a healthy child.
4. Discussion
The present study provides evidence that the P5L CFTR mu-
tation is associated with a mild CF phenotype. In fact, all patients
had normal respiratory function and pancreatic sufficiency.
Table 1
Demographic data of the patients.
Patient Sex Age BMI Height
(centiles)
Weight
(centiles)
Age of diagnosis Genotype Sweat Chloride
(mmol/L)
IRT
(ng/ml)
1 M 30 yrs 25.5 8 yrs ΔF508/P5L 87 NA
2 M 24 30.1 3 yrs ΔF508/P5L 120 NA
3 F 15 29.1 4 months ΔF508/P5L 46 NA
4 M 13 25.2 8 yrs ΔF508/P5L 79 NA
5 F 6 50° 75° Birth ΔF508/P5L 57 60/40
6 M 6 N97° 97° Birth W1282X/P5L 62 106/90
7 M 15 months 50° 50° Birth W1282X/P5L 57 94/42
BMI: body mass index.
IRT: immunoreactive trypsinogen, first week/third week after birth. Normal range values b60 ng/ml first week and b40 ng/ml third week.
Table 2
Clinical data of the patients.
Patient Fev1 (%) SaO2 (%) Bronchiectasis Sputum pathogens Rhino/sinus disease Pancreatic sufﬁciency Dehydration
1 101 97 Mild S. aureus, P. aeruginosa Yes Yes Yes (severe)
2 90 97 No No No Yes Yes
3 95 98 No S. aureus, P. aeruginosa No Yes Yes
4 86 97 No No No Yes No
5 NA 98 No No No Yes Yes
6 NA 98 No S. aureus No Yes Yes
7 NA 98 No S. aureus No Yes No
32 L. Spicuzza et al. / Journal of Cystic Fibrosis 11 (2012) 30–33The P5L mutation is one of the N-terminus CFTR missense
variants, first studied in the Spanish population [14]. Functional
classification of this mutation still remains controversial [10].
Some Spanish authors suggested that this mutation, along
with other N-terminus CFTR missense variants, may alter the
protein folding and/or trafficking/processing. However, these
authors found that although the expression of the P5L CFTR
mutant was reduced in the plasmatic membrane, still a small
but significant amount of mature protein was present [7]. Elec-
trophysiological analysis of the mature P5L CFRT fraction
revealed an altered channel activity and it has been speculated
that the N-terminus alteration may inhibit the channel's gating
processes [15]. Other authors included the P5L mutation in
the functional class II of the CFRT mutations, similar to the
common severe ΔF508 [16]. Although the different methodol-
ogies might explain these discrepancies, it seems unlikely that
the P5L variant might be included among deleterious muta-
tions. If it is true that the degree of organ involvement and
the severity of the disease are linked to the amount of functional
CFTR (and to organ's sensitivity to CFTR dysfunction) it is
likely that some functional protein must be present in our pa-
tients. It is noteworthy that all patients with the P5L variant
were bearing a severe mutation, causing loss of CFTR function
on the associated allele, thus confirming a protective role of this
variant on the phenotype. Most of the missense N-terminus mu-
tations have been described in Spanish patients, however de-
tails on the clinical phenotype are lacking. The only patient
reported so far is a 9-yr-old Spanish boy, with normal lung
function and pancreatic sufficiency [14].
The mild course the disease has been confirmed in the pre-
sent study as the two older patients maintained normal lungfunction and stable clinical condition over the time. It is also in-
triguing that the two male patients were fertile, since most of
the N-terminus missense variants have been associated with
congenital bilateral absence of vas deferens [7].
Indeed, although the correlation of genotype–phenotype in CF
has been extensively studied, it is difficult to predict for rare muta-
tions and, given the increasing number of mutations discovered,
understanding the role of genes on clinical outcomes is becoming
more challenging. In our patients we found abnormal/borderline
sweat test values along with one single allele mutation at basic ge-
netic test and this warranted further genetic search for the detection
of a second CFTR mutation. As the P5L is a rare and still unclas-
sified mutation, and given the association with a severe mutation
such as ΔF508, it is clear that only a follow-up of the patients
could allow definitive conclusion on the course of the disease. In-
deed our data confirm previous observations that the identification
of two CFTRmutations does not necessary settle the diagnostic is-
sues, and most of the consensus statements agree on the impor-
tance of the clinical condition, organ's involvement and
symptoms to make diagnosis of cystic fibrosis [1,17].
In conclusion, although it has been speculated that the N-
terminus CFTR missense variants may severely affect the be-
haviour of the CFTR chloride channel, patients with the P5L
CFTR mutation, in association with a severe class II mutation,
may be asymptomatic or affected by mild disease.References
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